Ability Pharma: Ability Pharma Seeks to Complete a Round of 7 Million

The current round has an investment commitment of up to €3 million, which includes the participation of the founding partners. The €7 million will make it possible to accelerate the regulatory path of ABTL0812 with additional toxicological studies and to study its antitumor immunomodulatory effects and initiate a program to identify new molecules with autophagy immunomodulatory properties.